Dishman Carbogen Amcis Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 9, 2025, 8:01 pm

Market Cap	3,368 Cr.
Current Price	215
High / Low	308/133
Stock P/E
Book Value	366
Dividend Yield	0.00 %
ROCE	0.02 %
ROE	2.64 %
Face Value	2.00
PEG Ratio	0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Dishman Carbogen Amcis Ltd

Competitors of Dishman Carbogen Amcis Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	6.71 Cr.	3.51	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/32.1	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	38.0 Cr.	26.0	29.0/8.74	38.8	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	70.4 Cr.	93.5	155/79.0	11.4	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,255.37 Cr	1,081.84		42.42	185.80	0.37%	16.00%	16.32%	6.27

All Competitor Stocks of Dishman Carbogen Amcis Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	562.08	568.99	540.61	613.96	639.79	618.56	723.38	586.59	651.09	654.71	523.78	789.04	682.34
Expenses	452.58	547.00	452.32	535.36	525.92	567.12	601.52	525.74	609.98	592.03	494.81	641.89	542.21
Operating Profit	109.50	21.99	88.29	78.60	113.87	51.44	121.86	60.85	41.11	62.68	28.97	147.15	140.13
OPM %	19.48%	3.86%	16.33%	12.80%	17.80%	8.32%	16.85%	10.37%	6.31%	9.57%	5.53%	18.65%	20.54%
Other Income	19.04	-7.77	5.67	8.85	3.97	-38.87	6.53	5.42	6.05	4.07	-4.01	3.69	7.67
Interest	15.11	15.64	19.18	20.17	21.91	24.43	28.45	27.49	33.08	30.95	31.93	36.63	48.78
Depreciation	74.95	83.88	75.08	79.57	50.33	75.74	70.45	75.04	80.37	85.00	70.59	72.09	71.97
Profit before tax	38.48	-85.30	-0.30	-12.29	45.60	-87.60	29.49	-36.26	-66.29	-49.20	-77.56	42.12	27.05
Tax %	8.06%	-47.69%	-1,436.67%	-18.23%	-2.98%	-19.27%	42.35%	12.80%	-10.05%	42.11%	0.01%	21.44%	82.88%
Net Profit	35.38	-44.62	4.01	-10.05	46.96	-70.72	17.00	-40.90	-59.63	-69.92	-77.57	33.09	4.63
EPS in Rs	2.26	-2.85	0.26	-0.64	3.00	-4.51	1.08	-2.61	-3.80	-4.46	-4.95	2.11	0.30

Last Updated: March 3, 2025, 4:43 pm

Below is a detailed analysis of the quarterly data for Dishman Carbogen Amcis Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹682.34 Cr.. The value appears to be declining and may need further review. It has decreased from 789.04 Cr. (Sep 2024) to ₹682.34 Cr., marking a decrease of 106.70 Cr..
For Expenses, as of Dec 2024, the value is ₹542.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 641.89 Cr. (Sep 2024) to ₹542.21 Cr., marking a decrease of 99.68 Cr..
For Operating Profit, as of Dec 2024, the value is ₹140.13 Cr.. The value appears to be declining and may need further review. It has decreased from 147.15 Cr. (Sep 2024) to ₹140.13 Cr., marking a decrease of 7.02 Cr..
For OPM %, as of Dec 2024, the value is 20.54%. The value appears strong and on an upward trend. It has increased from 18.65% (Sep 2024) to 20.54%, marking an increase of 1.89%.
For Other Income, as of Dec 2024, the value is ₹7.67 Cr.. The value appears strong and on an upward trend. It has increased from 3.69 Cr. (Sep 2024) to ₹7.67 Cr., marking an increase of ₹3.98 Cr..
For Interest, as of Dec 2024, the value is ₹48.78 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 36.63 Cr. (Sep 2024) to ₹48.78 Cr., marking an increase of ₹12.15 Cr..
For Depreciation, as of Dec 2024, the value is ₹71.97 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 72.09 Cr. (Sep 2024) to ₹71.97 Cr., marking a decrease of 0.12 Cr..
For Profit before tax, as of Dec 2024, the value is ₹27.05 Cr.. The value appears to be declining and may need further review. It has decreased from 42.12 Cr. (Sep 2024) to ₹27.05 Cr., marking a decrease of 15.07 Cr..
For Tax %, as of Dec 2024, the value is 82.88%. The value appears to be increasing, which may not be favorable. It has increased from 21.44% (Sep 2024) to 82.88%, marking an increase of 61.44%.
For Net Profit, as of Dec 2024, the value is ₹4.63 Cr.. The value appears to be declining and may need further review. It has decreased from 33.09 Cr. (Sep 2024) to ₹4.63 Cr., marking a decrease of 28.46 Cr..
For EPS in Rs, as of Dec 2024, the value is 0.30. The value appears to be declining and may need further review. It has decreased from ₹2.11 (Sep 2024) to 0.30, marking a decrease of ₹1.81.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:27 pm

Metric	Mar 2011	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	1,031	1,714	1,695	2,059	2,044	1,912	2,141	2,413	2,616	2,650
Expenses	830	1,261	1,249	1,507	1,540	1,638	1,809	2,081	2,329	2,271
Operating Profit	201	452	445	552	503	274	331	332	286	379
OPM %	20%	26%	26%	27%	25%	14%	15%	14%	11%	14%
Other Income	14	26	46	54	39	16	29	-20	22	11
Interest	56	49	49	57	62	48	57	86	120	148
Depreciation	69	214	211	240	283	308	308	281	311	300
Profit before tax	91	216	231	309	197	-65	-4	-55	-122	-58
Tax %	12%	33%	33%	32%	20%	154%	-524%	-45%	26%
Net Profit	80	145	155	210	159	-165	18	-30	-153	-110
EPS in Rs			9.58	13.03	10.10	-10.53	1.15	-1.90	-9.79	-7.00
Dividend Payout %	0%	0%	0%	2%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	6.90%	35.48%	-24.29%	-203.77%	110.91%	-266.67%	-410.00%
Change in YoY Net Profit Growth (%)	0.00%	28.59%	-59.77%	-179.49%	314.68%	-377.58%	-143.33%

Dishman Carbogen Amcis Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	5%
3 Years:	11%
TTM:	3%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	4%
TTM:	4%

Stock Price CAGR
10 Years:	%
5 Years:	26%
3 Years:	7%
1 Year:	-3%

Return on Equity
10 Years:	%
5 Years:	0%
3 Years:	-1%
Last Year:	-3%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 12:36 am

Month	Mar 2011	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	16	0.00	32	32	31	31	31	31	31	31
Reserves	863	4,814	5,075	5,347	5,684	5,667	5,518	5,778	5,596	5,705
Borrowings	868	950	1,095	1,042	1,357	1,589	1,830	2,209	2,313	2,507
Other Liabilities	334	811	967	899	1,121	1,068	1,255	1,421	1,631	1,937
Total Liabilities	2,081	6,574	7,169	7,321	8,193	8,356	8,634	9,439	9,571	10,180
Fixed Assets	1,012	4,852	5,066	5,098	5,678	5,698	5,773	6,188	6,724	7,159
CWIP	307	133	151	175	234	486	780	1,043	646	580
Investments	1	40	196	167	191	172	324	249	102	104
Other Assets	761	1,550	1,757	1,881	2,091	2,000	1,758	1,959	2,098	2,338
Total Assets	2,081	6,574	7,169	7,321	8,193	8,356	8,634	9,439	9,571	10,180

Below is a detailed analysis of the balance sheet data for Dishman Carbogen Amcis Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹31.00 Cr..
For Reserves, as of Sep 2024, the value is ₹5,705.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹5,596.00 Cr. (Mar 2024) to ₹5,705.00 Cr., marking an increase of 109.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹2,507.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹2,313.00 Cr. (Mar 2024) to ₹2,507.00 Cr., marking an increase of 194.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹1,937.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,631.00 Cr. (Mar 2024) to ₹1,937.00 Cr., marking an increase of 306.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹10,180.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹9,571.00 Cr. (Mar 2024) to ₹10,180.00 Cr., marking an increase of 609.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹7,159.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹6,724.00 Cr. (Mar 2024) to ₹7,159.00 Cr., marking an increase of 435.00 Cr..
For CWIP, as of Sep 2024, the value is ₹580.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹646.00 Cr. (Mar 2024) to ₹580.00 Cr., marking a decrease of 66.00 Cr..
For Investments, as of Sep 2024, the value is ₹104.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹102.00 Cr. (Mar 2024) to ₹104.00 Cr., marking an increase of 2.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹2,338.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,098.00 Cr. (Mar 2024) to ₹2,338.00 Cr., marking an increase of 240.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹10,180.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹9,571.00 Cr. (Mar 2024) to ₹10,180.00 Cr., marking an increase of 609.00 Cr..

Notably, the Reserves (₹5,705.00 Cr.) exceed the Borrowings (2,507.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2011	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	203	303	226	282	585	513	355	266	384
Cash from Investing Activity +	-231	-107	-297	-169	-442	-380	-619	-494	-230
Cash from Financing Activity +	25	-137	78	-102	-98	-11	130	250	-22
Net Cash Flow	-3	59	7	11	46	122	-133	22	132

Free Cash Flow

Month	Mar 2011	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-667.00	-498.00	444.00	551.00	502.00	273.00	330.00	330.00	284.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2011	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	60	61	96	79	103	80	81	89	64
Inventory Days	272	473	525	496	462	402	526	568	540
Days Payable	172	95	201	176	226	132	158	155	149
Cash Conversion Cycle	160	439	419	399	340	350	449	502	455
Working Capital Days	49	117	129	135	124	135	115	90	100
ROCE %			5%	6%	4%	0%	1%	1%	0%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%	59.32%
FIIs	4.60%	5.50%	5.85%	6.20%	7.20%	9.34%	8.90%	8.80%	8.60%	8.70%	8.05%	8.18%
DIIs	6.31%	6.91%	6.63%	4.26%	3.86%	2.55%	3.13%	3.51%	3.68%	2.36%	1.47%	1.22%
Public	29.77%	28.26%	28.19%	30.22%	29.61%	28.79%	28.65%	28.37%	28.39%	29.63%	31.17%	31.29%
No. of Shareholders	54,662	56,322	56,986	59,654	61,175	56,583	56,221	56,272	52,336	50,656	53,683	55,280

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
HSBC Flexi Cap Fund	2,377,050	0.96	33.73	681	2025-03-10	348952.86%
L&T Flexicap Fund - Regular Plan	2,377,050	0.81	23.47	681	2025-03-10	348952.86%
Motilal Oswal Nifty Microcap 250 Index Fund	63,747	0.2	0.9	681	2025-03-10	9260.79%
Motilal Oswal S&P BSE Healthcare ETF	681	0.12	0.01	681	2025-03-10	0%
Groww Nifty Total Market Index Fund	149	0.01	0	681	2025-03-10	-78.12%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	-9.79	-1.90	1.15	-10.53	10.10
Diluted EPS (Rs.)	-9.79	-1.90	1.15	-10.53	10.10
Cash EPS (Rs.)	10.04	16.00	20.77	9.11	28.13
Book Value[Excl.RevalReserv]/Share (Rs.)	358.90	370.51	353.89	363.44	364.25
Book Value[Incl.RevalReserv]/Share (Rs.)	358.90	370.51	353.89	363.44	364.25
Revenue From Operations / Share (Rs.)	166.82	153.89	136.52	121.94	130.25
PBDIT / Share (Rs.)	20.07	22.96	23.90	19.95	34.55
PBIT / Share (Rs.)	0.24	5.05	4.29	0.30	16.52
PBT / Share (Rs.)	-7.80	-3.48	-0.27	-4.15	12.57
Net Profit / Share (Rs.)	-9.79	-1.90	1.15	-10.53	10.10
NP After MI And SOA / Share (Rs.)	-9.79	-1.90	1.15	-10.53	10.10
PBDIT Margin (%)	12.03	14.91	17.50	16.35	26.52
PBIT Margin (%)	0.14	3.28	3.13	0.25	12.68
PBT Margin (%)	-4.67	-2.26	-0.19	-3.40	9.64
Net Profit Margin (%)	-5.86	-1.23	0.84	-8.63	7.75
NP After MI And SOA Margin (%)	-5.86	-1.23	0.84	-8.63	7.75
Return on Networth / Equity (%)	-2.72	-0.51	0.32	-2.89	2.77
Return on Capital Employeed (%)	0.05	1.03	0.93	0.06	3.90
Return On Assets (%)	-1.60	-0.31	0.20	-1.98	1.93
Long Term Debt / Equity (X)	0.04	0.18	0.13	0.08	0.04
Total Debt / Equity (X)	0.34	0.31	0.25	0.18	0.16
Asset Turnover Ratio (%)	0.27	0.26	0.04	0.03	0.08
Current Ratio (X)	0.75	1.07	1.29	1.33	1.13
Quick Ratio (X)	0.40	0.61	0.84	0.91	0.76
Inventory Turnover Ratio (X)	0.71	0.86	0.29	0.22	0.47
Dividend Payout Ratio (NP) (%)	0.00	0.00	0.00	0.00	2.03
Dividend Payout Ratio (CP) (%)	0.00	0.00	0.00	0.00	0.73
Earning Retention Ratio (%)	0.00	0.00	0.00	0.00	97.97
Cash Earning Retention Ratio (%)	0.00	0.00	0.00	0.00	99.27
Interest Coverage Ratio (X)	2.62	4.20	6.60	6.57	8.75
Interest Coverage Ratio (Post Tax) (X)	-0.22	1.21	1.57	-2.00	3.56
Enterprise Value (Cr.)	5245.26	3590.64	4151.85	2477.79	1609.53
EV / Net Operating Revenue (X)	2.01	1.49	1.94	1.30	0.78
EV / EBITDA (X)	16.67	9.97	11.08	7.92	2.97
MarketCap / Net Operating Revenue (X)	1.41	0.81	1.36	0.89	0.41
Retention Ratios (%)	0.00	0.00	0.00	0.00	97.96
Price / BV (X)	0.65	0.33	0.52	0.29	0.14
Price / Net Operating Revenue (X)	1.41	0.81	1.36	0.89	0.41
EarningsYield	-0.04	-0.01	0.01	-0.09	0.18

After reviewing the key financial ratios for Dishman Carbogen Amcis Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 24, the value is -9.79. This value is below the healthy minimum of 5. It has decreased from -1.90 (Mar 23) to -9.79, marking a decrease of 7.89.
For Diluted EPS (Rs.), as of Mar 24, the value is -9.79. This value is below the healthy minimum of 5. It has decreased from -1.90 (Mar 23) to -9.79, marking a decrease of 7.89.
For Cash EPS (Rs.), as of Mar 24, the value is 10.04. This value is within the healthy range. It has decreased from 16.00 (Mar 23) to 10.04, marking a decrease of 5.96.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 358.90. It has decreased from 370.51 (Mar 23) to 358.90, marking a decrease of 11.61.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 358.90. It has decreased from 370.51 (Mar 23) to 358.90, marking a decrease of 11.61.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 166.82. It has increased from 153.89 (Mar 23) to 166.82, marking an increase of 12.93.
For PBDIT / Share (Rs.), as of Mar 24, the value is 20.07. This value is within the healthy range. It has decreased from 22.96 (Mar 23) to 20.07, marking a decrease of 2.89.
For PBIT / Share (Rs.), as of Mar 24, the value is 0.24. This value is within the healthy range. It has decreased from 5.05 (Mar 23) to 0.24, marking a decrease of 4.81.
For PBT / Share (Rs.), as of Mar 24, the value is -7.80. This value is below the healthy minimum of 0. It has decreased from -3.48 (Mar 23) to -7.80, marking a decrease of 4.32.
For Net Profit / Share (Rs.), as of Mar 24, the value is -9.79. This value is below the healthy minimum of 2. It has decreased from -1.90 (Mar 23) to -9.79, marking a decrease of 7.89.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -9.79. This value is below the healthy minimum of 2. It has decreased from -1.90 (Mar 23) to -9.79, marking a decrease of 7.89.
For PBDIT Margin (%), as of Mar 24, the value is 12.03. This value is within the healthy range. It has decreased from 14.91 (Mar 23) to 12.03, marking a decrease of 2.88.
For PBIT Margin (%), as of Mar 24, the value is 0.14. This value is below the healthy minimum of 10. It has decreased from 3.28 (Mar 23) to 0.14, marking a decrease of 3.14.
For PBT Margin (%), as of Mar 24, the value is -4.67. This value is below the healthy minimum of 10. It has decreased from -2.26 (Mar 23) to -4.67, marking a decrease of 2.41.
For Net Profit Margin (%), as of Mar 24, the value is -5.86. This value is below the healthy minimum of 5. It has decreased from -1.23 (Mar 23) to -5.86, marking a decrease of 4.63.
For NP After MI And SOA Margin (%), as of Mar 24, the value is -5.86. This value is below the healthy minimum of 8. It has decreased from -1.23 (Mar 23) to -5.86, marking a decrease of 4.63.
For Return on Networth / Equity (%), as of Mar 24, the value is -2.72. This value is below the healthy minimum of 15. It has decreased from -0.51 (Mar 23) to -2.72, marking a decrease of 2.21.
For Return on Capital Employeed (%), as of Mar 24, the value is 0.05. This value is below the healthy minimum of 10. It has decreased from 1.03 (Mar 23) to 0.05, marking a decrease of 0.98.
For Return On Assets (%), as of Mar 24, the value is -1.60. This value is below the healthy minimum of 5. It has decreased from -0.31 (Mar 23) to -1.60, marking a decrease of 1.29.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.18 (Mar 23) to 0.04, marking a decrease of 0.14.
For Total Debt / Equity (X), as of Mar 24, the value is 0.34. This value is within the healthy range. It has increased from 0.31 (Mar 23) to 0.34, marking an increase of 0.03.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.27. It has increased from 0.26 (Mar 23) to 0.27, marking an increase of 0.01.
For Current Ratio (X), as of Mar 24, the value is 0.75. This value is below the healthy minimum of 1.5. It has decreased from 1.07 (Mar 23) to 0.75, marking a decrease of 0.32.
For Quick Ratio (X), as of Mar 24, the value is 0.40. This value is below the healthy minimum of 1. It has decreased from 0.61 (Mar 23) to 0.40, marking a decrease of 0.21.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.71. This value is below the healthy minimum of 4. It has decreased from 0.86 (Mar 23) to 0.71, marking a decrease of 0.15.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Interest Coverage Ratio (X), as of Mar 24, the value is 2.62. This value is below the healthy minimum of 3. It has decreased from 4.20 (Mar 23) to 2.62, marking a decrease of 1.58.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -0.22. This value is below the healthy minimum of 3. It has decreased from 1.21 (Mar 23) to -0.22, marking a decrease of 1.43.
For Enterprise Value (Cr.), as of Mar 24, the value is 5,245.26. It has increased from 3,590.64 (Mar 23) to 5,245.26, marking an increase of 1,654.62.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.01. This value is within the healthy range. It has increased from 1.49 (Mar 23) to 2.01, marking an increase of 0.52.
For EV / EBITDA (X), as of Mar 24, the value is 16.67. This value exceeds the healthy maximum of 15. It has increased from 9.97 (Mar 23) to 16.67, marking an increase of 6.70.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.41. This value is within the healthy range. It has increased from 0.81 (Mar 23) to 1.41, marking an increase of 0.60.
For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Price / BV (X), as of Mar 24, the value is 0.65. This value is below the healthy minimum of 1. It has increased from 0.33 (Mar 23) to 0.65, marking an increase of 0.32.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.41. This value is within the healthy range. It has increased from 0.81 (Mar 23) to 1.41, marking an increase of 0.60.
For EarningsYield, as of Mar 24, the value is -0.04. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 23) to -0.04, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Dishman Carbogen Amcis Ltd as of March 12, 2025 is: ₹118.27

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Dishman Carbogen Amcis Ltd is Overvalued by 44.99% compared to the current share price 215.00

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Dishman Carbogen Amcis Ltd as of March 12, 2025 is: 159.99

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Dishman Carbogen Amcis Ltd is Overvalued by 25.59% compared to the current share price 215.00

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: 35.28%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (5,004.70 cr) compared to borrowings (1,576.00 cr), indicating strong financial stability. The company has shown consistent growth in sales (1.60 cr) and profit (74.00 cr) over the years.	The stock has a low average ROCE of 1.89%, which may not be favorable. The stock has a high average Working Capital Days of 110.44, which may not be favorable. The stock has a high average Cash Conversion Cycle of 390.33, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dishman Carbogen Amcis Ltd:
1. Net Profit Margin: -5.86%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 0.05% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -2.72% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): -0.22
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.4
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 0 (Industry average Stock P/E: 42.42)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.34
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Dishman Carbogen Amcis Ltd. is a Public Limited Listed company incorporated on 17/07/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L74900GJ2007PLC051338 and registration number is 051338. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 327.35 Cr. and Equity Capital is Rs. 31.36 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Dishman Corporate House, Iscon-Bopal Road, Ahmedabad Gujarat 380058	dishman@dishmangroup.com www.imdcal.com

Management
Name	Position Held
Mr. Janmejay R Vyas	Chairman
Mr. Arpit J Vyas	Global Managing Director
Mrs. Deohooti J Vyas	Whole Time Director
Mr. Rajendra S Shah	Independent Director
Mr. Subir Kumar Das	Independent Director
Mr. Maitri K Mehta	Independent Director

FAQ

What is the latest intrinsic value of Dishman Carbogen Amcis Ltd?

The latest intrinsic value of Dishman Carbogen Amcis Ltd as on 12 March 2025 is ₹118.27, which is 44.99% lower than the current market price of 215.00, indicating the stock is overvalued by 44.99%. The intrinsic value of Dishman Carbogen Amcis Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹3,368 Cr. and recorded a high/low of ₹308/133 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹5,705 Cr and total liabilities of ₹10,180 Cr.

What is the Market Cap of Dishman Carbogen Amcis Ltd?

The Market Cap of Dishman Carbogen Amcis Ltd is 3,368 Cr..

What is the current Stock Price of Dishman Carbogen Amcis Ltd as on 12 March 2025?

The current stock price of Dishman Carbogen Amcis Ltd as on 12 March 2025 is ₹215.

What is the High / Low of Dishman Carbogen Amcis Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Dishman Carbogen Amcis Ltd stocks is ₹308/133.

What is the Stock P/E of Dishman Carbogen Amcis Ltd?

The Stock P/E of Dishman Carbogen Amcis Ltd is .

What is the Book Value of Dishman Carbogen Amcis Ltd?

The Book Value of Dishman Carbogen Amcis Ltd is 366.

What is the Dividend Yield of Dishman Carbogen Amcis Ltd?

The Dividend Yield of Dishman Carbogen Amcis Ltd is 0.00 %.

What is the ROCE of Dishman Carbogen Amcis Ltd?

The ROCE of Dishman Carbogen Amcis Ltd is 0.02 %.

What is the ROE of Dishman Carbogen Amcis Ltd?

The ROE of Dishman Carbogen Amcis Ltd is 2.64 %.

What is the Face Value of Dishman Carbogen Amcis Ltd?

The Face Value of Dishman Carbogen Amcis Ltd is 2.00.